Lumiphore

Lumiphore is a biotechnology company focused on developing innovative radiopharmaceuticals using proprietary chelation technology, providing solutions for diagnostics and therapeutic applications in the medical sector. Founded in 2001 and headquartered in Berkeley, US, Lumiphore specializes in advancing radiopharmaceuticals. The company has adapted its strategies over the years to align with market needs and has raised funding through several rounds, with the most recent deal occurring on August 30, 2007. The firm was founded by Stephane Petoud, who has a background in biotechnology.

Lumiphore specializes in the development of next-generation radiopharmaceuticals through its proprietary chelation technology. The company’s core product offerings include preorganized macrocyclic BiFunctional Chelates (mBFC), designed for radiothernostic applications that combine optimized scaffolds and bidentate chelation structures. These chelates provide high in-vivo stability, enabling simple labeling of targeting agents and easy incorporation of radionuclides at temperatures below 37°C, preserving the integrity of the targeting agents. Lumiphore's innovative compounds are particularly suited for diagnostics and drug discovery, serving sectors that require high sensitivity and stability, such as Mix-N-Read diagnostics and High Content Screening (HCS) programs, primarily in North America and Europe.

Lumiphore operates as a revenue-stage biotechnology company, generating income through partnerships and collaborations with entities in the medical and pharmaceutical sectors. The company engages in business transactions involving B2B partnerships, providing proprietary chelation technology and radiopharmaceuticals to research institutions and pharmaceutical companies. These transactions often include milestone payments and licensing fees for the use of Lumiphore’s technology and products, facilitating an ongoing revenue stream while expanding its market presence in diagnostics and therapeutics. Following its most recent funding round on August 30, 2007, which raised capital from Nanostart Investments, Lumiphore plans to leverage this support to enhance its product development efforts.

The company is focused on expanding its product offerings and aims to enter new markets in Asia and South America by the end of 2025. This strategic expansion will be pivotal in establishing Lumiphore's presence in regions that are increasingly demanding advanced radiopharmaceutical solutions.